Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine if LY03005 is effective and safe in improve MADRS score, as compared to placebo (no medicine) in participants with Major Depressive Disorder (MDD)


Clinical Trial Description

The study consisted of two periods: a screening period of 1 week and a double-blind treatment period (8 weeks). After the screening period, 588 enrolled subjects were randomized into one of 3 study groups in the 1:1:1 ratio, 2 LY03005 treatment groups with different dose or 1 placebo group. Subjects were given investigatory drug or placebo according to the protocol, followed up at the end of 1, 2, 4 6, and 8 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04853407
Study type Interventional
Source Luye Pharma Group Ltd.
Contact
Status Completed
Phase Phase 3
Start date December 5, 2018
Completion date December 24, 2020

See also
  Status Clinical Trial Phase
Completed NCT00316160 - Sexual Functioning Study With Antidepressants Phase 4
Active, not recruiting NCT03642964 - A Study in Patients With Major Depressive Disorder Phase 2
Completed NCT01912196 - Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Phase 2
Completed NCT00958204 - Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression Phase 3
Completed NCT00102492 - Study Of GW679769 In Major Depressive Disorder Phase 2
Completed NCT02012218 - Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy Phase 3
Completed NCT01477203 - Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders Phase 4
Terminated NCT01123707 - To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD) Phase 3
Completed NCT00768430 - Optimization of IV Ketamine for Treatment Resistant Depression Phase 2
Completed NCT00559299 - Patient Tolerability Study of GSK163090 Phase 1
Completed NCT04403373 - Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study N/A
Completed NCT00330616 - Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan Phase 2
Recruiting NCT03012724 - Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD) N/A
Completed NCT02380066 - Comparison of Anyu Peibo With Placebo in Treatment of MDD Phase 2
Not yet recruiting NCT02395263 - Comparison of Yuxintine With Placebo in Treatment of MDD Phase 2
Completed NCT01187407 - A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment Phase 3
Completed NCT00448292 - A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder Phase 2
Completed NCT00057239 - An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder Phase 2
Recruiting NCT03087916 - Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder Phase 3
Completed NCT01683019 - Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression N/A